The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

Depression is one of the most common mental illness in the United States. It affects more than 20 million people a year.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...